Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 13, 2026
Bitmine Immersion Technologies (BMNR): Could Shares Reach +34% Toward the $24 Level?

Bitmine Immersion Technologies (BMNR): Could Shares Reach +34% Toward the $24 Level?

Key Takeaways

  • The selected stock price target is $24, about 34% above BMNR's recent close near $17.89.
  • $24 sits just below the lowest current Wall Street 12-month analyst target of $25 and near a widely discussed $23–$24 resistance zone.
  • The strongest bullish factors are Bitmine's massive Ethereum treasury, growing staking revenue, and Russell 1000 inclusion.
  • The biggest risks are direct exposure to Ethereum price swings, steep reported losses, share dilution, and extreme volatility.
  • Key technical levels are support at $13–$14 and resistance at $17.50–$18; a decisive breakout above $18 would open the path toward $23–$24.
  • For investors, $24 is ambitious but not disconnected from analyst models; it would likely require a sustained Ethereum rally, not just a short-term bounce.

Why the $24 Target Draws Attention

BMNR's 52-week range of $12.80 to $71.74 shows how sharply the stock has moved. A push to $24 would deliver meaningful upside from the recent close without needing a return to the prior peak. That positions the level as a practical checkpoint rather than an unrealistic stretch.

The target also aligns with the broader analyst picture. According to MarketBeat, the consensus 12-month analyst price target sits near $27.65, with a range from $25 to $30.30. S&P Global data points to an average near $31.87. In short, $24 sits on the conservative side of published Wall Street estimates, which gives the discussion added weight.

BMNR as an Ethereum Treasury Vehicle

Although Bitmine started as a Bitcoin mining and immersion-cooling operation, it now positions itself primarily as an Ethereum treasury company. Its “alchemy of 5%” approach aims for ownership of 5% of Ethereum’s circulating supply. By late July 2026, the company reported holding roughly 5.79 million ETH, plus Bitcoin, cash, and equity stakes, bringing total disclosed crypto and cash holdings to about $11.8 billion.

That figure is relevant because BMNR’s market capitalization has recently hovered near $10.8 billion, so the shares have traded at a modest discount to the stated value of holdings. The stock effectively functions in part as a leveraged play on Ethereum rather than solely as an operating business.

Bitmine has also developed a staking operation via its MAVAN validator network. Staking and validation revenue reached $45.7 million in the fiscal third quarter, representing about 98% of total revenue and roughly four times the prior quarter. Management has guided for annualized staking revenue between $211 million and $246 million, depending on deployment scale.

Potential Drivers Toward $24

The clearest catalyst remains a sustained increase in Ethereum’s price. Analysts at Cantor Fitzgerald and B. Riley have noted that near-term upside depends primarily on Ethereum appreciation rather than operational gains alone. Because BMNR holds millions of ETH, a higher token price directly lifts the value of the treasury and can support the stock.

Staking execution is the next key factor. Continued growth in staking revenue, paired with evidence that the platform can cover preferred-stock obligations, could shift valuation toward recurring cash flow instead of pure token-price beta.

Index inclusion provides an additional structural boost. Bitmine joined the Russell 1000 Index in late June 2026, which management and market observers have tied to greater passive-fund demand and wider institutional ownership.

Technical momentum also plays a role. Market commentary has flagged $17.50–$18 as a critical resistance zone. A decisive close above $18 could reframe the narrative from recovery to breakout, bringing the $23–$24 area into focus. Short interest near 8% of the float could amplify any upside move through forced covering.

Obstacles That Could Limit the Advance

The bear case centers on BMNR’s high correlation to Ethereum. If ETH weakens, treasury value declines, the discount could persist or widen, and the recovery thesis stalls. The company has also posted steep quarterly losses, including a recent $128.25 per share loss on $46.53 million in revenue, illustrating how digital-asset accounting can distort reported results.

Dilution remains another headwind. Preferred-stock issuance and an increased share count affect per-share metrics and can pressure the common equity. Weiss Ratings has kept a sell rating, reflecting ongoing skepticism about the fundamental profile.

From a technical standpoint, failure to clear $18 would likely keep the stock rangebound, while a break below the $13–$14 support zone could trigger a retest of the 52-week low and push the $24 target further out of reach.

Key Technical Levels to Watch

The most important support level sits in the $13–$14 zone, where the stock has stabilized after prior selling pressure. Holding above $14 is necessary to maintain the recovery structure.

The most important resistance level is $17.50–$18. This area previously acted as support before the correction and now represents the hurdle bulls must reclaim. Beyond that zone, the next major supply area is $23–$24, combining a psychological round number with prior chart resistance.

Monitoring BMNR with Tickeron Tools

I also checked this setup using Tickeron’s AI tools to see how the patterns compare across the sector. The platform’s AI-driven signals help track evolving conditions without reviewing every chart manually.

AI Daily Buy/Sell Signals

In my own research process, I frequently reference AI Daily Buy/Sell Signals from Tickeron when following names like BMNR. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from market behavior, technical patterns, and AI analysis. It serves as a practical way to spot shifts, track positions, and identify changing trends alongside other research steps.

Final Assessment

A move toward $24 looks plausible yet conditional. The target sits below most published analyst price targets, and the stock has recently traded near or below the stated value of its crypto holdings. The main supporting elements remain Ethereum price strength, expanding staking revenue, passive inflows from Russell 1000 inclusion, and a technical breakout above $18.

The risks are equally straightforward: Ethereum exposure cuts both ways, reported losses and dilution complicate the fundamentals, and the $18 resistance remains unbroken. Investors should track Ethereum’s trend, quarterly staking revenue, share-count changes, and whether BMNR can hold the $13–$14 support while testing the $17.50–$18 resistance zone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BMNR

BMNR in upward trend: price rose above 50-day moving average on July 27, 2026

BMNR moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend. In of 79 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 09, 2026. You may want to consider a long position or call options on BMNR as a result. In of 132 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for BMNR crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMNR advanced for three days, in of 137 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 96 cases where BMNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 77 cases where BMNR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMNR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BMNR broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMNR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.930) is normal, around the industry mean (4.225). P/E Ratio (0.000) is within average values for comparable stocks, (21.556). BMNR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.672). Dividend Yield (0.001) settles around the average of (0.033) among similar stocks. P/S Ratio (104.167) is also within normal values, averaging (31.137).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was 1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -10%. DOMH experienced the highest price growth at 23%, while VIP experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 70
Price Growth Rating: 63
SMR Rating: 76
Profit Risk Rating: 85
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
BMNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry InvestmentBanksBrokers

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.